{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:55:29Z","timestamp":1778748929105,"version":"3.51.4"},"reference-count":145,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cardiometabolic disorders (CMD) is a constellation of metabolic predisposing\n                    factors for atherosclerosis such as insulin resistance (IR) or diabetes mellitus\n                    (DM), systemic hypertension, central obesity, and dyslipidemia. Cardiometabolic\n                    diseases (CMDs) continue to be the leading cause of mortality in both developed\n                    and developing nations, accounting for over 32% of all fatalities\n                    globally each year. Furthermore, dyslipidemia, angina, arrhythmia, heart\n                    failure, myocardial infarction (MI), and diabetes mellitus are the major causes\n                    of death, accounting for an estimated 19 million deaths in 2012. CVDs will kill\n                    more than 23 million individuals each year by 2030. Nonetheless, new drug\n                    development (NDD) in CMDs has been increasingly difficult in recent decades due\n                    to increased costs and a lower success rate. Drug repositioning in CMDs looks\n                    promising in this scenario for launching current medicines for new therapeutic\n                    indications. Repositioning is an ancient method that dates back to the 1960s and\n                    is mostly based on coincidental findings during medication trials. One\n                    significant advantage of repositioning is that the drug\u2019s safety profile\n                    is well known, lowering the odds of failure owing to undesirable toxic effects.\n                    Furthermore, repositioning takes less time and money than NDD. Given these\n                    facts, pharmaceutical corporations are becoming more interested in medication\n                    repositioning. In this follow-up, we discussed the notion of repositioning and\n                    provided some examples of repositioned medications in cardiometabolic\n                    disorders.<\/jats:p>","DOI":"10.1055\/a-1971-6965","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T23:42:08Z","timestamp":1672875728000},"page":"7-24","source":"Crossref","is-referenced-by-count":7,"title":["Repurposing of Drugs for Cardiometabolic Disorders: An Out and Out\n                    Cumulation"],"prefix":"10.1055","volume":"55","author":[{"given":"Rufaida","family":"Wasim","sequence":"additional","affiliation":[{"name":"Pharmacology, Integral University, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarique Mahmood","family":"Ansari","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Integral University, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Haris","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Bioengineering, Integral University, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farogh","family":"Ahsan","sequence":"additional","affiliation":[{"name":"Pharmacology, Integral University, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshiya","family":"Shamim","sequence":"additional","affiliation":[{"name":"Pharmacology, Integral University, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Singh","sequence":"additional","affiliation":[{"name":"Pharmaceutics, Integral University, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Shariq","sequence":"additional","affiliation":[{"name":"Pharmacy, Integral University, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aamir","family":"Anwar","sequence":"additional","affiliation":[{"name":"Pharmacy, Integral University, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aquib Rehanullah","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Pharmacy, Integral University, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saba","family":"Parveen","sequence":"additional","affiliation":[{"name":"Pharmacology, Integral University, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrd3776","article-title":"Drug repurposing programmes get lift off","volume":"11","author":"A Mullard","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/448645a","article-title":"New uses for old drugs","volume":"448","author":"C R Chong","year":"2007","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/bph.13798","article-title":"Drug repurposing from the perspective of pharmaceutical companies","volume":"175","author":"Y Cha","year":"2018","journal-title":"Br J Pharmacol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.semcancer.2019.09.012","article-title":"Drug repurposing for breast cancer therapy: Old weapon for new battle","volume":"68","author":"S Aggarwal","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.0b013e31824e8f0d","article-title":"Amantadine: The journey from fighting flu to treating Parkinson disease","volume":"78","author":"G Hubsher","year":"2012","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"e16739","DOI":"10.2196\/16739","article-title":"Understanding drug repurposing from the perspective of biomedical entities and\n                    their evolution: bibliographic research using aspirin","volume":"8","author":"J Yang","year":"2020","journal-title":"JMIR Med Inform"},{"key":"ref7","first-page":"493","article-title":"Cyclosporine in transplantation \u2013 A history of converging timelines","volume":"25","author":"D Colombo","year":"2012","journal-title":"J Boil Regul Homeost Agents"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40257-014-0077-5","article-title":"Androgenetic alopecia: an evidence-based treatment update","volume":"15","author":"S Varothai","year":"2014","journal-title":"Am. J Clin Dermatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.bjc.6601507","article-title":"Cancer treatment with kinase inhibitors: What have we learnt from imatinib?","volume":"90","author":"D M Ross","year":"2004","journal-title":"Br J Cancer"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.drudis.2016.06.021","article-title":"Drug repositioning approaches to parasitic diseases: a medicinal chemistry\n                    perspective","volume":"21","author":"L G Ferreira","year":"2016","journal-title":"Drug Discov Today"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"T T Ashburn","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1471-2164-15-S4-S5","article-title":"GWAS and drug targets","volume":"15","author":"C Cao","year":"2014","journal-title":"BMC Genom"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.1158140","article-title":"Drug target identification using side-effect similarity","volume":"321","author":"M Campillos","year":"2008","journal-title":"Science"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41576-019-0127-1","article-title":"Benefits and limitations of genome-wide association studies","volume":"20","author":"V Tam","year":"2019","journal-title":"Nat Rev Genet"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.coph.2019.12.004","article-title":"Next-generation drug repurposing using human genetics and network biology","volume":"51","author":"S Nabirotchkin","year":"2020","journal-title":"Curr Opin Pharmacol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1002\/mds.23388","article-title":"Gender differences in Parkinson\u2019s disease: clinical characteristics and\n                    cognition","volume":"25","author":"I N Miller","year":"2010","journal-title":"Mov Disord"},{"key":"ref17","first-page":"1","article-title":"Translating GWAS findings to novel therapeutic targets for coronary artery\n                    disease","volume":"5","author":"L Shu","year":"2018","journal-title":"Front Cardiovasc Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1021\/ci400047w","article-title":"DockoMatic 2.0: high throughput inverse virtual screening and homology\n                    modeling","volume":"53","author":"C Bullock","year":"2013","journal-title":"J Chem Inf Model"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12859-018-2153-y","article-title":"SPIDR: Small-molecule peptide-influenced drug repurposing","volume":"19","author":"M D King","year":"2018","journal-title":"BMC Bioinform"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nchembio806","article-title":"A clinical drug library screen identifies astemizole as an antimalarial\n                    agent","volume":"2","author":"C R Chong","year":"2006","journal-title":"Nat Chem Biol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.2174\/15680266113136660162","article-title":"Discovering new treatments for Alzheimer\u2019s disease by repurposing\n                    approved medications","volume":"13","author":"B S Appleby","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"117652","DOI":"10.1016\/j.lfs.2020.117652","article-title":"In silico studies on therapeutic agents for COVID-19: drug repurposing\n                    approach","volume":"20","author":"B Shah","year":"2020","journal-title":"Life Sci"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.maturitas.2009.12.013","article-title":"Levels of vitamin D and cardiometabolic disorders: systematic review and\n                    meta-analysis","volume":"65","author":"J Parker","year":"2010","journal-title":"Maturitas"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1161\/01.CIR.100.10.1134","article-title":"Diabetes and cardiovascular disease a statement for healthcare professionals\n                    from the American Heart Association","volume":"100","author":"S M Grundy","year":"1999","journal-title":"Circulation"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s11906-003-0085-y","article-title":"Cardiometabolic syndrome: pathophysiology and treatment","volume":"5","author":"J P Castro","year":"2003","journal-title":"Curr Hypertens Rep"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/vhrm.2006.2.1.69","article-title":"Metabolic effects of the incretin mimetic exenatide in the treatment of type 2\n                    diabetes","volume":"2","author":"A S Catherine","year":"2006","journal-title":"Vasc Health Risk Manag"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/dom.12050","article-title":"Extra-pancreatic effects of incretin-based therapies: potential benefit for\n                    cardiovascular-risk management in type 2 diabetes","volume":"15","author":"R E van Genugten","year":"2013","journal-title":"Diabet Obes Metab"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/dom.12175","article-title":"Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a\n                    meta-analysis of randomized clinical trials","volume":"16","author":"M Monami","year":"2014","journal-title":"Diabet Obes Metab"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2337\/dc10-1393","article-title":"Risk of cardiovascular disease events in patients with type 2 diabetes\n                    prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice\n                    daily or other glucose-lowering therapies: a retrospective analysis of the\n                    LifeLink database","volume":"34","author":"J H Best","year":"2011","journal-title":"Diabet Care"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/dom.12085","article-title":"Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and\n                    liraglutide: a meta-analysis of clinical trials","volume":"15","author":"B Wang","year":"2013","journal-title":"Diabet Obes Metab"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"piie001986","DOI":"10.1136\/bmjopen-2012-001986","article-title":"Effects of exenatide and liraglutide on heart rate, blood pressure and body\n                    weight: systematic review and meta-analysis","volume":"3","author":"L E Robinson","year":"2013","journal-title":"BMJ Open"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4239\/wjd.v4.i5.190","article-title":"Effects of glucagon-like peptide-1 receptor agonists on renal function","volume":"4","author":"T D Filippatos","year":"2013","journal-title":"World J Diabet"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.regpep.2004.08.024","article-title":"Glucagon-like peptide-1 relaxes rat conduit arteries via an\n                    endothelium-independent mechanism","volume":"125","author":"T Nystrom","year":"2005","journal-title":"Regul Pept"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrcardio.2011.211","article-title":"The effect of glucagon-like peptide 1 on cardiovascular risk","volume":"9","author":"J Sivertsen","year":"2012","journal-title":"Nat Rev Cardiol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nm.3128","article-title":"GLP-1 receptor activation and epac2 link atrial natriuretic peptide secretion to\n                    control of blood pressure","volume":"19","author":"M Kim","year":"2013","journal-title":"Nat Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1530\/EC-13-0087","article-title":"Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy\n                    males","volume":"3","author":"J Skov","year":"2014","journal-title":"Endocrine Connect"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.2337\/dc09-1961","article-title":"Improvement of postprandial endothelial function after a single dose of\n                    exenatide in individuals with impaired glucose tolerance and recent-onset type 2\n                    diabetes","volume":"33","author":"J Koska","year":"2010","journal-title":"Diabet Care"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1161\/01.CIR.0000139339.85840.DD","article-title":"Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and\n                    improves left ventricular performance in conscious dogs with pacing-induced\n                    dilated cardiomyopathy","volume":"110","author":"L A Nikolaidis","year":"2004","journal-title":"Circ"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/01.CIR.0000120505.91348.58","article-title":"Effects of glucagon-like peptide-1 in patients with acute myocardial infarction\n                    and left ventricular dysfunction after successful reperfusion","volume":"109","author":"L A Nikolaidis","year":"2004","journal-title":"Circ"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.cardfail.2006.08.211","article-title":"Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and\n                    functional status in patients with chronic heart failure","volume":"12","author":"G G Sokos","year":"2006","journal-title":"J Cardiac Failure"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2337\/db08-1193","article-title":"GLP-1R agonist liraglutide activates cytoprotective pathways and improves\n                    outcomes after experimental myocardial infarction in mice","volume":"58","author":"M H Noyan-Ashraf","year":"2009","journal-title":"Diabetes."},{"key":"ref47","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1475-2840-9-76","article-title":"Glucagon-like peptide-1 and the exenatide analogue ac3174 improve cardiac\n                    function, cardiac remodeling, and survival in rats with chronic heart\n                    failure","volume":"9","author":"Q Liu","year":"2010","journal-title":"Cardiovasc Diabetol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1479-5876-11-84","article-title":"Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion\n                    injury studies","volume":"11","author":"P Wohlfart","year":"2013","journal-title":"J Trans Med"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/eurheartj\/ehr309","article-title":"Exenatide reduces reperfusion injury in patients with ST-segment elevation\n                    myocardial infarction","volume":"33","author":"J Lonborg","year":"2012","journal-title":"Eur Heart J"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1464-5491.2008.02484.x","article-title":"Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1\n                    analogue, on cardiovascular risk biomarkers in patients with type 2\n                    diabetes","volume":"25","author":"J P Courreges","year":"2008","journal-title":"Diabet Med J Br Diabet Assoc"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.2337\/dc09-2361","article-title":"Exenatide affects circulating cardiovascular risk biomarkers independently of\n                    changes in body composition","volume":"33","author":"M C Bunck","year":"2010","journal-title":"Diabet Care"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1586\/eem.13.20","article-title":"Longer acting GLP-1 receptor agonists and the potential for improved\n                    cardiovascular outcomes: a review of current literature","volume":"8","author":"C A Tibble","year":"2013","journal-title":"Expert Rev Endocrinol Metab"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bbi.2014.04.001","article-title":"Obesity and neuroinflammation: a pathway to cognitive impairment","volume":"42","author":"A A Miller","year":"2014","journal-title":"Brain Behav Immun"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ecl.2013.09.006","article-title":"Relationships between diabetes and cognitive impairment","volume":"43","author":"S M de la Monte","year":"2014","journal-title":"Endocrinol Metab Clin North Am."},{"key":"ref56","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1185\/03007995.2010.549466","article-title":"Neuroprotective properties of GLP-1: theoretical and practical applications","volume":"27","author":"J J Holst","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"T31","DOI":"10.1530\/JOE-13-0221","article-title":"Central effects of GLP-1: new opportunities for treatments of neurodegenerative\n                    diseases","volume":"221","author":"C Holscher","year":"2014","journal-title":"J Endocrinol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","article-title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model\n                    of Alzheimer\u2019s disease","volume":"31","author":"P L McClean","year":"2011","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood\n                    brain barrier and enhance neurogenesis","volume":"13","author":"K Hunter","year":"2012","journal-title":"BMC Neurosci"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.neurobiolaging.2010.02.014","article-title":"Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in\n                    APP\/ps1 mice","volume":"33","author":"S Gengler","year":"2012","journal-title":"Neurobiol Aging"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3233\/JAD-2010-1314","article-title":"GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and\n                    cytotoxicity in cellular and animal models of Alzheimer\u2019s disease","volume":"19","author":"Y Li","year":"2010","journal-title":"J Alzheimer\u2019s Dis"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson\u2019s disease","volume":"123","author":"I Aviles-Olmos","year":"2013","journal-title":"J Clin Investig"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrneph.2013.272","article-title":"The gut-renal axis: do incretin-based agents confer renoprotection in\n                    diabetes?","volume":"10","author":"M H Muskiet","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1210\/endo.134.5.8156917","article-title":"Divergent tissue-specific and developmental expression of receptors for glucagon\n                    and glucagon-like peptide-1 in the mouse","volume":"134","author":"R V Campos","year":"1994","journal-title":"Endocrinology"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"F355","DOI":"10.1152\/ajprenal.00729.2010","article-title":"Mechanisms mediating the diuretic and natriuretic actions of the incretin\n                    hormone glucagon-like peptide-1","volume":"301","author":"R O Crajoinas","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.regpep.2006.12.016","article-title":"Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular\n                    cells","volume":"141","author":"P Schlatter","year":"2007","journal-title":"Regulat Pept"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.3168\/jds.2011-5311","article-title":"Short communication: expression of peptide YY, proglucagon, neuropeptide Y\n                    receptor y2, and glucagon-like peptide-1 receptor in bovine peripheral\n                    tissues","volume":"95","author":"A Pezeshki","year":"2012","journal-title":"J Dairy Sci"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/00004872-200306000-00012","article-title":"Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive\n                    rats","volume":"21","author":"M Yu","year":"2003","journal-title":"J Hypertens"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1210\/jc.2003-031403","article-title":"Glucagon-like peptide 1 induces natriuresis in healthy subjects and in\n                    insulin-resistant obese men","volume":"89","author":"J P Gutzwiller","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"F963","DOI":"10.1152\/ajprenal.00259.2012","article-title":"Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is\n                    mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice","volume":"303","author":"T Rieg","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11154-014-9287-7","article-title":"Effects of GLP-1 in the kidney","volume":"15","author":"J Skov","year":"2014","journal-title":"Rev Endocr Metab Disord"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/IJNRD.S39739","article-title":"Obesity, hypertension, and chronic kidney disease","volume":"7","author":"M E Hall","year":"2014","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/j.ackd.2010.10.003","article-title":"Hypertension in diabetic nephropathy: epidemiology, mechanisms, and\n                    management","volume":"18","author":"P N Van Buren","year":"2011","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.metabol.2012.03.002","article-title":"GLP-1 analog liraglutide protects against oxidative stress and albuminuria in\n                    streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of\n                    renal NAD(P)H oxidases","volume":"61","author":"H Hendarto","year":"2012","journal-title":"Metab Clin Exp"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-010-2028-x","article-title":"Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its\n                    anti-inflammatory action without lowering blood glucose level in a rat model of\n                    type 1 diabetes","volume":"54","author":"R Kodera","year":"2011","journal-title":"Diabetologia"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1681\/ASN.2006070778","article-title":"Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates\n                    diabetic nephropathy through improving metabolic anomalies in db\/db\n                    mice","volume":"18","author":"C W Park","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.2337\/db11-1824","article-title":"Protective effects of GLP-1 on glomerular endothelium and its inhibition by\n                    PKCbeta activation in diabetes","volume":"61","author":"A Mima","year":"2012","journal-title":"Diabetes"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1210\/jc.2011-1508","article-title":"Exenatide exerts a potent antiinflammatory effect","volume":"97","author":"A Chaudhuri","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1124\/dmd.110.034066","article-title":"Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog\n                    liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl\n                    peptidase IV and neutral endopeptidase","volume":"38","author":"M Malm-Erjefalt","year":"2010","journal-title":"Drug Metab Disposit Biol Fate Chem"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jdiacomp.2012.12.005","article-title":"Potential of incretin-based therapies for non-alcoholic fatty liver disease","volume":"27","author":"S L Samson","year":"2013","journal-title":"J Diabet Compl"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"e003995","DOI":"10.1136\/bmjopen-2013-003995","article-title":"Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study\n                    protocol for a phase II multicentre, double-blinded, randomised, controlled\n                    trial","volume":"3","author":"M J Armstrong","year":"2013","journal-title":"BMJ Open"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/hepr.12351","article-title":"Pilot study of liraglutide effects in non-alcoholic steatohepatitis and\n                    non-alcoholic fatty liver disease with glucose intolerance in Japanese patients\n                    (LEAN-J)","volume":"45","author":"Y Eguchi","year":"2015","journal-title":"Hepatol Res Off J Jpn Soc Hepatol Res"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.ajpath.2012.07.015","article-title":"The glucagon-like peptide-1 receptor agonist exendin 4 has a protective role in\n                    ischemic injury of lean and steatotic liver by inhibiting cell death and\n                    stimulating lipolysis","volume":"181","author":"N A Gupta","year":"2012","journal-title":"Am J Pathol"},{"key":"ref88","first-page":"405","article-title":"Empagliflozin for type 2 diabetes mellitus: an overview of phase 3 clinical\n                    trials","volume":"13","author":"J L Matthew","year":"2017","journal-title":"Curr Diabetes Rev"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/dom.12494","article-title":"Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week,\n                    randomized, placebo-controlled trial (EASE-1)","volume":"17","author":"T R Pieber","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40264-014-0161-z","article-title":"Cardiovascular effects of drugs used to treat Alzheimer\u2019s disease","volume":"37","author":"L G Howes","year":"2014","journal-title":"Drug Saf"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/clpt.2010.98","article-title":"The effect of donepezil treatment on cardiovascular mortality","volume":"88","author":"K Sato","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/FJC.0b013e3182609a74","article-title":"Influences of donepezil on cardiovascular system\u2013possible therapeutic\n                    benefits for heart failure \u2013 donepezil cardiac test registry (DOCTER)\n                    study","author":"T Kubo","year":"2012","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/eht182","article-title":"The use of cholinesterase inhibitors and the risk of myocardial infarction and\n                    death: a nationwide cohort study in subjects with Alzheimer\u2019s\n                    disease","volume":"34","author":"P Nordstr\u00f6m","year":"2013","journal-title":"Eur Heart J"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000357124","article-title":"Cardioprotection and anticholinesterases in patients with Alzheimer\u2019s\n                    disease: time for reappraisal","volume":"4","author":"F Monacelli","year":"2014","journal-title":"Dement Geriatr Cognit Dis Extra"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"FUTURE 1 study group, secukinumab inhibition of interleukin-17A in patients with\n                    psoriatic arthritis","volume":"373","author":"P J Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"MEASURE 1 Study Group, MEASURE 2 Study Group, Secukinumab, an interleukin-17A\n                    inhibitor, in ankylosing spondylitis","volume":"373","author":"D Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cjca.2019.06.021","article-title":"Effects of interleukin 17A inhibition on myocardial deformation and vascular\n                    function in psoriasis","volume":"36","author":"G Makavos","year":"2019","journal-title":"Can J Cardiol"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of secukinumab on endothelial dysfunction and other cardiovascular\n                    disease parameters in psoriasis patients over 52 weeks","volume":"139","author":"E von Stebut","year":"2019","journal-title":"J Invest Dermatol"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/ced.14180","article-title":"Effect of biologics targeting IL-23\/IL17 axis on subclinical\n                    atherosclerosis: results of a pilot study","volume":"45","author":"M Marovt","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1007\/s12325-019-01118-x","article-title":"tocilizumab effects on coagulation factor XIII in patients with rheumatoid\n                    arthritis","volume":"36","author":"R Gualtierotti","year":"2019","journal-title":"Adv Ther"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.trsl.2016.12.003","article-title":"Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis\n                    patients modulating endothelial dysfunction, NETosis, and inflammation","volume":"183","author":"P Ruiz-Lim\u00f3n","year":"2017","journal-title":"Transl Res"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#","article-title":"High incidence of cardiovascular events in a rheumatoid arthritis cohort not\n                    explained by traditional cardiac risk factors","volume":"44","author":"K Williams","year":"2001","journal-title":"Arthritis Rheum"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1345\/aph.10263","article-title":"Colesevelam hydrochloride: a novel bile acid-binding resin","volume":"35","author":"M A Aldridge","year":"2001","journal-title":"Ann Pharmacother"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1463-1326.2009.01181.x","article-title":"Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical\n                    evidence","volume":"12","author":"V A Fonseca","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2337\/dc08-0283","article-title":"Colesevelam HCl improves glycemic control and reduces LDL cholesterol in\n                    patients with inadequately controlled type 2 diabetes on sulfonylurea-based\n                    therapy","volume":"31","author":"V A Fonseca","year":"2008","journal-title":"Diabetes care"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.3402\/jchimp.v2i3.19081","article-title":"History of current non-insulin medications for diabetes mellitus","volume":"2","author":"C C Quianzon","year":"2012","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/17425255.2012.672973","article-title":"Evaluation of colesevelam hydrochloride for the treatment of type 2\n                    diabetes","volume":"8","author":"L M Younk","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1742-1241.2011.02635.x","article-title":"Weight change with long-term duloxetine use in chronic painful conditions: an\n                    analysis of 16 clinical studies","volume":"65","author":"P Gaynor","year":"2011","journal-title":"Int J Clin Pract"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40265-021-01665-0","article-title":"Association of metformin with the mortality and incidence of cardiovascular\n                    events in patients with pre-existing cardiovascular diseases","volume":"82","author":"T Li","year":"2022","journal-title":"Drugs"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: A systematic review and\n                    meta-analysis","volume":"1","author":"L Yan","year":"2013","journal-title":"Biomed Rep"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1021\/acschemneuro.1c00091","article-title":"Repurposing a cardiovascular disease drug of cloridarol as hIAPP inhibitor","volume":"12","author":"T Yijing","year":"2021","journal-title":"ACS chem. Neurosci"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients\n                    with nonalcoholic fatty liver disease","volume":"115","author":"K L Donnelly","year":"2005","journal-title":"J Clin Invest"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature09291","article-title":"Anti-diabetic drugs inhibit obesity -linked phosphorylation of PPARgamma by\n                    Cdk5","volume":"466","author":"J H Choi","year":"2010","journal-title":"Nature"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature10383","article-title":"Antidiabetic actions of a non -agonist PPARgamma ligand blocking Cdk5 -mediated\n                    phosphorylation","volume":"477","author":"J H Choi","year":"2011","journal-title":"Nature"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/liv.13634","article-title":"Dual PPARalpha\/gamma agonist saroglitazar improves liver histopathology\n                    and biochemistry in experimental NASH models","volume":"38","author":"M R Jain","year":"2017","journal-title":"Liver Int"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1517\/14656566.2015.1009894","article-title":"Saroglitazar for the treatment of dyslipidemia in diabetic patients","volume":"16","author":"S R Joshi","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/bcpt.13190","article-title":"A role of peroxisome proliferator-activated receptor \u2013 in non-alcoholic\n                    fatty liver disease","volume":"124","author":"J Skat-R\u00f8rdam","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.yjmcc.2019.04.003","article-title":"Histone deacetylases in cardiovascular and metabolic diseases","volume":"130","author":"R A Bagchia","year":"2019","journal-title":"J Mol Cell Cardiol"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.coph.2017.04.003","article-title":"Emerging role of monoamine oxidase as a therapeutic target for cardiovascular\n                    disease","volume":"33","author":"D Soni","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.npep.2011.03.004","article-title":"Multiple opioid receptors mediate the hypotensive response induced by central\n                    5-HT 3 receptor stimulation","volume":"45","author":"J B Fregoneze","year":"2011","journal-title":"Neuropeptides"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1210\/jc.2004-2554","article-title":"Acute pressor and hormonal effects of betaendorphin at high doses in healthy and\n                    hypertensive subjects: role of opioid receptor agonism","volume":"90","author":"D Cozzolino","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"ref124","first-page":"282","article-title":"Modulation of peripheral adrenergic neurotransmission by\n                    methionine-enkephalin","volume":"221","author":"R R Gaddis","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"ref125","first-page":"1","article-title":"Bidirectional effects of endogenous opioid peptides on endothelin release in\n                    porcine aortic endothelial cell culture: mediation by opioid receptor and opioid\n                    receptor antagonistinsensitive mechanisms","volume":"272","author":"R M Arendt","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/01.CIR.103.6.850","article-title":"Chronic delta-opioid receptor stimulation in humans decreases muscle sympathetic\n                    nerve activity","volume":"103","author":"P Kienbaum","year":"2001","journal-title":"Circulation"},{"key":"ref127","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0014-2999(86)90048-8","article-title":"Cardiovascular and endocrine effects of naloxone compared in normotensive and\n                    hypertensive patients","volume":"126","author":"N Fuenmayor","year":"1986","journal-title":"Eur J Pharmacol"},{"key":"ref129","doi-asserted-by":"crossref","first-page":"26807","DOI":"10.1038\/srep26807","article-title":"k-opioid receptor stimulation improves endothelial function via akt-stimulated\n                    no production in hyperlipidemic rats","volume":"6","author":"F Tian","year":"2016","journal-title":"Sci Rep"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1592\/phco.20.4.270.34882","article-title":"Orlistat, a new lipase inhibitor for the management of obesity","volume":"20","author":"A M Heck","year":"2000","journal-title":"Pharmacotherapy"},{"key":"ref132","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S2213-8587(17)30236-X","article-title":"Progress and challenges in anti-obesity pharmacotherapy","volume":"6","author":"D H Bessesen","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref133","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.phrs.2017.05.022","article-title":"Effect of orlistat on plasma lipids and body weight: a systematic review and\n                    meta-analysis of 33 randomized controlled trials","volume":"122","author":"A Sahebkar","year":"2017","journal-title":"Pharmacol Res"},{"key":"ref134","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1053\/j.gastro.2017.12.024","article-title":"Effects of weight-loss medications on cardiometabolic risk profiles: a\n                    systematic review and network meta-analysis","volume":"154","author":"R Khera","year":"2018","journal-title":"Gastroenterology"},{"key":"ref135","doi-asserted-by":"crossref","first-page":"e13399","DOI":"10.1111\/ijcp.13399","article-title":"Effectiveness and tolerability of orlistat and liraglutide in patients with\n                    obesity in a real-world setting: the XENSOR Study","volume":"73","author":"J J Gorgojo-Martinez","year":"2019","journal-title":"Int J Clin Pract"},{"key":"ref136","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/phar.2048","article-title":"Observational comparative effectiveness of pharmaceutical treatments for obesity\n                    within the Veterans Health Administration","volume":"38","author":"T R Grabarczyk","year":"2018","journal-title":"Pharmacotherapy"},{"key":"ref138","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.tips.2013.03.004","article-title":"Challenges and opportunities of drug repositioning","volume":"34","author":"N Novac","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"ref139","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1126\/science.332.6037.1492","article-title":"NIH\u2019s second-hand shop for tried-and-tested drugs","volume":"332","author":"K J Biomedicine","year":"2011","journal-title":"Science"},{"key":"ref140","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1517\/13543784.15.11.1295","article-title":"Complementary new approaches enable repositioning of failed drug candidates","volume":"15","author":"L A Tartaglia","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/bph.13798","article-title":"Drug repurposing from the perspective of pharmaceutical companies: drug\n                    repurposing in pharmaceutical companies","volume":"175","author":"Y Cha","year":"2018","journal-title":"Br J Pharmacol"},{"key":"ref143","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.drudis.2018.11.022","article-title":"The drug repurposing landscape from 2012 to 2017: evolution, challenges, and\n                    possible solutions","volume":"24","author":"P Polamreddy","year":"2019","journal-title":"Drug Discov Today"},{"key":"ref145","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrd3776","article-title":"Drug repurposing programmes get lift of","volume":"11","author":"A Mullard","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"ref146","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrd4412","article-title":"Bank tests drug development waters","volume":"13","author":"A Mullard","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"ref147","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/534314a","article-title":"Can you teach old drugs new tricks?","volume":"534","author":"N Nosengo","year":"2016","journal-title":"Nature"},{"key":"ref148","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nrd4707","article-title":"Pioneering government-sponsored drug repositioning collaborations: progress and\n                    learning","volume":"14","author":"D E Frail","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"ref149","doi-asserted-by":"crossref","first-page":"e00510","DOI":"10.1002\/prp2.510","article-title":"Compound asset sharing initiatives between pharmaceutical companies, funding\n                    bodies, and academia: learnings and successes","volume":"7","author":"A G Hayes","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"ref150","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.tips.2013.03.004","article-title":"Challenges and opportunities of drug repositioning","volume":"34","author":"N Novac","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1517\/13543784.2014.998335","article-title":"Discontinued anxiolytic drugs (2009\u20132014)","volume":"24","author":"R Mandrioli","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"ref152","doi-asserted-by":"crossref","first-page":"102cm29","DOI":"10.1126\/scitranslmed.3002939","article-title":"Disclosure of clinical trial results when product development is abandoned","volume":"3","author":"M A Rogawski","year":"2011","journal-title":"Sci Transl Med"},{"key":"ref153","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1525\/cmr.2013.55.4.83","article-title":"Recovering abandoned compounds through expanded external IP licensing","volume":"55","author":"H Chesbrough","year":"2013","journal-title":"Calif Manage Rev"},{"key":"ref154","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ddstr.2011.06.006","article-title":"The CTSA Pharmaceutical Assets Portal \u2013 a public-private partnership\n                    model for drug repositioning","volume":"8","author":"K Marusina","year":"2011","journal-title":"Drug Discov Today Ther Strateg Winter"},{"key":"ref155","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"S Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"ref156","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ddstr.2011.06.004","article-title":"Cheminformatic\/bioinformatic analysis of large corporate databases:\n                    application to drug repurposing","volume":"8","author":"W Loging","year":"2011","journal-title":"Drug Discov Today Ther Strateg"},{"key":"ref157","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.ebiom.2015.10.003","volume":"2","year":"2015","journal-title":"EBioMedicine"},{"key":"ref158","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/490015a","article-title":"New cures sought from old drugs","volume":"490","author":"M Wadman","year":"2012","journal-title":"Nature"},{"key":"ref159","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drudis.2015.09.017","article-title":"Drugrepositioning opportunities for cancer therapy: novel molecular targets for\n                    known compounds","volume":"21","author":"R W\u00fcrth","year":"2016","journal-title":"Drug Discov Today"},{"key":"ref160","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1377\/hlthaff.24.3.622","article-title":"Why are pharmaceutical companies gradually abandoning vaccines?","volume":"24","author":"P A Oft","year":"2005","journal-title":"Health Af (Millwood)"},{"key":"ref161","first-page":"385","article-title":"The future of drug repositioning: old drugs, new opportunities","volume":"46","author":"T L Doan","year":"2011","journal-title":"Annu Rep Med Chem"},{"key":"ref162","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.pain.2012.04.014","article-title":"Randomized control trial of topical clonidine for treatment of painful diabetic\n                    neuropathy","volume":"153","author":"C M Campbell","year":"2012","journal-title":"PAIN"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1971-6965.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T23:43:00Z","timestamp":1672875780000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1971-6965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":145,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2023,1,4]]},"published-print":{"date-parts":[[2023,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1971-6965","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"value":"0018-5043","type":"print"},{"value":"1439-4286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}